Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.

Cancer cell - 4 Aug 2009

Venkitaraman Ashok R

Abstract excerpt

Targeted therapies exploiting specific molecular defects in cancer cells promise to overcome roadblocks in the development of effective anticancer drugs. A recent report in the New England Journal of Medicine on the early clinical evaluation of Olaparib in cancers lacking the BRCA1 or BRCA2 genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Clinical Trials, Phase I as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Germ-Line Mutation

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 19647219
DOI: 10.1016/j.ccr.2009.07.011

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19647219-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.PMID 19647219Read ↗

FDA approves olaparib for germline BRCA-mutated metastatic breast cancerSemantic proximity Read ↗

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 MutationSemantic proximity Read ↗

New Therapeutic Options for BRCA Mutant PatientsSemantic proximity Read ↗

Olaparib for Metastatic Germline BRCA-Mutated Breast CancerSemantic proximity Read ↗

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationSemantic proximity Read ↗

PARP inhibition outside of BRCA mutation carriers.Semantic proximity Read ↗

First PARP Inhibitor Ok'd for Breast CancerSemantic proximity Read ↗

BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.Semantic proximity Read ↗

Olaparib for the treatment of breast cancer.Semantic proximity Read ↗

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation CarriersSemantic proximity Read ↗

Olaparib shows promise in multiple tumor types.Semantic proximity Read ↗

The Yin and Yang of treating BRCA-deficient tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.